Core Insights - Booking Holdings (BKNG) is set to report its fourth-quarter 2025 results on February 18, with revenue estimates at $6.11 billion, reflecting an 11.73% year-over-year growth, and earnings per share (EPS) estimated at $48.23, indicating a 16.08% increase from the previous year [1][2] Group 1: Financial Performance Expectations - The Zacks Consensus Estimate for revenues is $6.11 billion, suggesting an 11.73% growth from the same quarter last year [1] - The consensus estimate for earnings is $48.23 per share, indicating a 16.08% increase year-over-year, with a recent upward revision of 5 cents in the past 30 days [1] - The company has consistently beaten earnings estimates in the last four quarters, with an average beat of 18.21% [2] Group 2: Operational Momentum and Strategic Initiatives - Booking Holdings is expected to have entered Q4 2025 with strengthening operational momentum, driven by strategic initiatives in loyalty and multi-vertical expansion [3] - The Genius loyalty program is anticipated to show robust engagement, with higher conversion rates and repeat booking behavior from travelers in Levels 2 and 3 [3] - The direct channel mix is projected to be in the mid-60% range, contributing to marketing efficiency and reduced customer acquisition costs [3] Group 3: Market Trends and Growth Projections - The Connected Trip vision is gaining momentum, with multi-vertical booking behavior accelerating, particularly in flight tickets and attractions, which are growing faster than accommodation bookings [4] - Room night growth is expected to moderate between 4% and 6% due to normalization of the booking window, indicating a slowdown in growth [5] - Revenue growth is projected between 10% and 12%, facing challenges from a higher mix of lower-margin flight and attractions bookings, which may pressure overall take rates and margins [5] Group 4: Earnings ESP and Stock Outlook - According to the Zacks model, Booking Holdings has an Earnings ESP of +1.01% and a Zacks Rank of 3 (Hold), which suggests a moderate likelihood of an earnings beat [6] - The company is positioned within a competitive landscape, with other stocks like Nutrien and Analog Devices also showing favorable earnings outlooks [7][9]

Core Insights - Bruker Corporation (BRKR) reported adjusted earnings per share (EPS) of 59 cents for Q4 2025, a decline of 22.4% year over year, and missed the Zacks Consensus Estimate by 9.2% [1][7] - The company’s total revenues for Q4 were $977.2 million, a slight decrease of 0.2% year over year, but exceeded the Zacks Consensus Estimate by 1.12% [3][10] - For the full year 2025, adjusted EPS was $1.83, down 24.1% from the previous year [2] Revenue Analysis - Q4 revenues by geography showed a 13.8% decline in the U.S. to $225 million, while Europe saw a 1% increase to $377 million, and Asia Pacific revenues rose 8.3% to $301.2 million [4] - The BSI BioSpin segment revenues fell 2% to $267 million, while BSI CALID revenues increased by 3.4% to $331.6 million [4] - Total revenues for 2025 reached $3.44 billion, reflecting a 2.1% increase from the previous year [3] Margin Performance - Gross profit decreased by 8.9% to $449.2 million, with gross margin contracting by 439 basis points to 46% due to an 8.6% rise in the cost of revenues [5][10] - Adjusted operating profit was $102.4 million, down 27.7% year over year, with adjusted operating margin contracting by 398 basis points to 10.5% [5] Financial Position - At the end of Q4 2025, Bruker had cash and cash equivalents of $298.8 million, an increase from $183.4 million at the end of 2024 [6] - Long-term debt at the end of Q4 2025 was $1.87 billion, down from $2.09 billion at the end of Q4 2024 [8] 2026 Guidance - Bruker provided guidance for 2026, expecting revenues between $3.57 billion and $3.60 billion, indicating a year-over-year growth of 4% to 5% [9] - Adjusted EPS for 2026 is projected to be in the range of $2.10 to $2.15, representing an increase of 15% to 17% year over year [9] Overall Assessment - The company ended Q4 2025 with mixed results, as earnings missed estimates while revenues surpassed them [10] - Margins were negatively impacted by lower volume, unfavorable mix, tariffs, and currency headwinds [10] - Despite challenges, Bruker’s innovation efforts showed promise, with expectations for improved contributions from the BEST segment in 2026 [11]

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Haverty Furniture, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - Haverty Furniture is expected to report quarterly earnings of $0.48 per share, reflecting a year-over-year increase of 2.1% [3]. - Revenues are projected to be $197.47 million, which is a 7.1% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4]. - The Most Accurate Estimate aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likelihood of actual earnings deviating from consensus estimates, with positive readings being more predictive [9][10]. - Haverty Furniture currently has a Zacks Rank of 4, complicating predictions of an earnings beat [12]. Historical Performance - In the last reported quarter, Haverty Furniture exceeded expectations by delivering earnings of $0.28 per share against an expected $0.24, resulting in a surprise of 16.67% [13]. - Over the past four quarters, the company has consistently beaten consensus EPS estimates [14]. Market Context - The broader retail home furnishings industry is also seeing varied performance, with Floor & Dcor expected to report earnings of $0.36 per share, reflecting a year-over-year decline of 7.7% [18]. - Floor & Dcor's revenue is anticipated to be $1.14 billion, a 2.7% increase from the previous year, but it has a negative Earnings ESP of -1.56% [19][20].

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Oneok Inc. despite higher revenues, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - Oneok is expected to report quarterly earnings of $1.49 per share, reflecting a year-over-year decrease of 5.1%, while revenues are projected to be $9.49 billion, an increase of 35.6% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 2.62% over the last 30 days, indicating a bearish sentiment among analysts regarding the company's earnings prospects [4][11]. Earnings Surprise Prediction - The Zacks Earnings ESP for Oneok is -0.72%, suggesting analysts have become more pessimistic, and the stock holds a Zacks Rank of 4, complicating predictions of an earnings beat [11]. Historical Performance - In the last reported quarter, Oneok exceeded the expected earnings of $1.46 per share by delivering $1.49, resulting in a surprise of +2.05%. Over the past four quarters, the company has beaten consensus EPS estimates twice [12][13]. Market Reaction Factors - An earnings beat or miss alone may not dictate stock movement, as other factors can influence investor sentiment. Stocks may decline despite an earnings beat or rise despite a miss [14][16].

Core Viewpoint - Ovintiv (OVV) is expected to report a year-over-year decline in earnings due to lower revenues, with the consensus outlook being crucial for assessing the company's earnings picture [1][2] Earnings Expectations - The upcoming earnings report is anticipated to be released on February 23, with expected earnings of $0.98 per share, reflecting a year-over-year decrease of 27.4% [3] - Revenues are projected to be $1.95 billion, down 11% from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has been revised 2.67% higher in the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for Ovintiv is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +0.44% [12] Historical Performance - In the last reported quarter, Ovintiv exceeded the expected earnings of $0.97 per share by delivering $1.03, resulting in a surprise of +6.19% [13] - Over the past four quarters, the company has beaten consensus EPS estimates three times [14] Predictive Indicators - A positive Earnings ESP is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10] - However, Ovintiv currently holds a Zacks Rank of 5, making it challenging to predict a beat despite the positive Earnings ESP [12] Conclusion - Ovintiv does not appear to be a compelling earnings-beat candidate, and investors should consider other factors when making decisions regarding the stock ahead of the earnings release [17]

Company Overview - Axsome Therapeutics (AXSM) is expected to report a year-over-year increase in earnings due to higher revenues for the quarter ended December 2025, with a consensus outlook indicating a quarterly loss of $0.70 per share, representing a 27.1% improvement from the previous year [1][3] - Revenues are anticipated to reach $193.01 million, reflecting a significant increase of 62.5% compared to the same quarter last year [3] Earnings Estimates and Revisions - The consensus EPS estimate has been revised 7.1% higher in the last 30 days, indicating a positive reassessment by analysts regarding the company's earnings prospects [4] - The Most Accurate Estimate for Axsome is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +30.00%, suggesting a strong likelihood of beating the consensus EPS estimate [12] Earnings Surprise History - In the last reported quarter, Axsome was expected to post a loss of $0.82 per share but actually reported a loss of $0.94, resulting in a surprise of -14.63% [13] - Over the past four quarters, the company has successfully beaten consensus EPS estimates three times [14] Industry Context - In the Zacks Medical - Biomedical and Genetics industry, Insmed (INSM) is also expected to report a loss of $1.07 per share for the same quarter, with a year-over-year change of +18.9% and anticipated revenues of $263.87 million, up 152.7% from the previous year [18][19] - Insmed's consensus EPS estimate has been revised 37.1% higher in the last 30 days, resulting in an Earnings ESP of +7.01%, indicating a likelihood of beating the consensus EPS estimate [19][20]

Quaker Chemical (KWR) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Febru ...

The market expects Erie Indemnity (ERIE) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on February 23, might help the stock move higher if these key numbers are ...

Core Viewpoint - Hims & Hers Health, Inc. (HIMS) is anticipated to report a year-over-year decline in earnings despite an increase in revenues, which could significantly influence its stock price in the near term [1][2]. Earnings Expectations - The upcoming earnings report is scheduled for February 23, and it may lead to a stock price increase if the results exceed expectations; conversely, a miss could result in a decline [2]. - The consensus estimate for quarterly earnings is projected at $0.02 per share, reflecting a year-over-year decrease of 81.8%. Revenues are expected to reach $619.19 million, marking a 28.7% increase from the previous year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised down by 8.51%, indicating a reassessment by analysts regarding the company's earnings outlook [4]. - The Most Accurate Estimate for Hims & Hers Health is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -153.01%, suggesting a bearish sentiment among analysts [12]. Earnings Surprise History - In the last reported quarter, Hims & Hers Health was expected to post earnings of $0.09 per share but only achieved $0.06, resulting in a surprise of -33.33% [13]. - The company has only beaten consensus EPS estimates once in the last four quarters [14]. Conclusion - Hims & Hers Health does not appear to be a strong candidate for an earnings beat, and investors should consider additional factors when making decisions regarding this stock ahead of the earnings release [17].

Kratos (KTOS) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on February 23, might help the stock move higher if these key numbers are better than expectat ...